Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events

Table 1 Results of haplotype analysis among UGT1A1, UGT1A6, UGT1A7, and UGT1A9

		UGT subfamily	1A1						1A6	1A7	1A7		1A9
		Site	Enhancer	Enhancer	Promoter	Promoter	Exon1	Exon1		Exon1	Exon1	Promoter	Promoter
		Allele	*60			*28	*6	*27	*2	*2	*3
		Polymorphism	-3279T>G	-3156G>A	-364C>T	insTA	211G>A	686C>A	19T>G	387T>G	387T>G	-57T>G	-118(T)9>10
									541A>G	391C>A	391C>A
									552A>C	392C>A	392C>A
											622T>C
Authors	Ethnicity	Frequency
Sai et al[19]	Japanese	0.146					X
		0.121	X	X	X	X
			X			X
Minami et al[16]	Japanese	0.138	X			X		X
						X
Kitagawa et al[58]	Asian	ND		X		X
	Caucasian	ND		X		X
	Japanese	0.097	X			X
Kaniwa et al[31]	African	0.446	X			X
	American
	Caucasian	0.389	X			X
Innocenti et al[57]	African	0.26	X	X		X
	American
Kohle et al[62]	Caucasian	0.285				X			X		X
		0.15					X				X	X
Fujita et al[17]	Japanese	0.05				X					X	X
		0.03					X				X
		0.02				X							X
Carlini et al[26]	ND	0.234				X			X		X
Huang et al[61]	Asian + Caucasian	ND					X				X
Cecchin et al[60]a	Caucasian	0.232	X			X

ND; not described; ^aUGT1A7 (387T>G) and UGT1A7 (622T>C) in addition to UGT1A1*93 and X; Linkage disequilibrium is designated by X.